PMGC it has schedules a pre-IND meeting with FDA for EL-22

Northstrive Biosciences announced that it has scheduled a pre-Investigational New Drug, IND, meeting with the U.S. Food and Drug Administration for Wednesday, April 23, 2025. Northstrive will have a Type B pre-IND meeting with the FDA to discuss the path forward for filing an IND for EL-22 as a combination treatment with GLP-1 for muscle preservation. “The scheduled pre-IND meeting is a crucial step in our development of EL-22 and underscores our commitment to advancing this potential breakthrough therapy,” said Deniel Mero, Co-founder of Northstrive Biosciences. “We expect to walk away from the meeting with a clear path for moving into human trials, targeting one of obesity’s biggest unmet needs; the preservation of muscle for patients on GLP-1 therapies.”